Peptides for fitness and skin: separating TikTok hype from real data

What did @brad_davidd actually say?

Brad walks through three peptides he takes daily: GHK-Cu for skin, scar tissue, and collagen; BPC-157 for injury healing; and TB-500 for recovery. He frames this as a personal protocol built around heavy training, grappling five days a week plus striking four. He claims GHK-Cu "helps prevent acne, gives you more collagen" and has "deaging properties," and says BPC-157 stacked with TB-500 handles "healing injuries" and "injury prevention." He keeps it brief and personal, which is actually more responsible than most peptide content on this platform. He does not dose on camera, does not name a supplier, and does not claim to treat any diagnosed condition. That restraint matters.

Does the science back this up?

Partially, and the degree varies a lot by peptide. GHK-Cu has the strongest human-adjacent evidence. BPC-157 and TB-500 are in a different league, research-wise, and that distinction is worth understanding before you inject anything.

GHK-Cu (copper tripeptide-1) has legitimate supporting data. Pickart and Margolina (2018, Cosmetics) reviewed decades of research showing GHK-Cu stimulates collagen and elastin synthesis, activates wound-healing pathways, and modulates matrix metalloproteinases involved in scar remodeling. Relevant to Brad's scar claim: a 2009 study by Leyden et al. in the Journal of Cosmetic Dermatology found topical GHK-Cu improved skin laxity and appearance in human subjects. The acne prevention claim is thinner but not fabricated. GHK-Cu has documented anti-inflammatory activity, which can indirectly reduce acne-related inflammation, though no randomized controlled trial has specifically tested it for acne prevention.

BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. The healing data looks compelling, but almost entirely in rodent models. Sikiric et al. have published extensively (most recently 2023, Current Pharmaceutical Design) on tendon, ligament, and gut repair in rats. There is no published randomized human trial on BPC-157 as of mid-2025. That is a meaningful gap.

TB-500 (thymosin beta-4 fragment) follows a similar pattern. Animal studies, mostly in cardiac and musculoskeletal tissue, show repair-promoting activity. Human evidence remains limited to a few small pilot trials, none in healthy athletic populations.

What did they get wrong (or right)?

Brad deserves credit for accuracy on the mechanism. Calling GHK-Cu a "copper peptide" for skin and scar tissue tracks with the actual pharmacology. Framing BPC-157 and TB-500 as injury-recovery tools is consistent with how the research community discusses them, even if that research is mostly preclinical.

Where he oversimplifies: saying GHK-Cu "helps prevent acne" as if this is an established finding is ahead of the data. It is plausible given the anti-inflammatory profile, but prevention is a strong word for a mechanism-only claim. The "deaging properties" line is vague enough that it is hard to call wrong, but it blurs the line between topical cosmetic use (where there is real data) and systemic injectable use (where there is not).

The bigger issue he skips: BPC-157 and TB-500 are not FDA-approved. They are used off-label through compounding pharmacies, and their regulatory status has shifted. The FDA placed BPC-157 on its list of substances that cannot be compounded as of 2023. Whether someone can actually access this stack legally depends entirely on jurisdiction and sourcing. Brad does not mention any of this. For a 5,000-view video, that gap could send people to gray-market sources without realizing the risk.

What should you actually know?

These are not supplements. They are peptides administered by injection in most protocols, which means sterility, dosing precision, and sourcing matter in ways that do not apply to a protein powder. The absence of human clinical trials for BPC-157 and TB-500 does not mean they do not work, but it does mean no one has formally established what a safe dose looks like in humans, what the interaction profile is, or what the long-term effects are.

GHK-Cu is the outlier here. It has a longer safety history, genuine cosmetic and dermatological literature behind it, and is used in topical formulations that are not injected. If someone is interested in GHK-Cu specifically for skin and scar concerns, there is a reasonable body of evidence to discuss with a licensed provider.

For BPC-157 and TB-500, the conversation with a provider is not optional. These are not something to self-administer based on a TikTok stack video, even a responsible one. The regulatory picture alone, quite apart from the science, makes physician oversight necessary.